News | PET-CT | October 25, 2017

New guidelines focus on appropriate imaging procedure for restaging and treatment response assessment of malignant disease

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria

October 25, 2017 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/CT (positron emission tomography/computed tomography) in restaging and treatment response assessment of malignant disease. As cancer patients move through therapy, FDG PET/CT has proven an effective tool for assessing treatment response and updating the stage of malignancy. This AUC aims to improve utilization and guide providers across specialties in its use. 

This is the fourth in a series of new AUC developed by SNMMI in its role as a qualified provider-led entity (PLE) under the Medicare Appropriate Use Criteria Program for Advanced Diagnostic Imaging. The society’s other recently released AUC are for bone scintigraphy in prostate and breast cancerventilation/perfusion (V/Q) imaging in pulmonary embolism, which is endorsed by the American College of Emergency Physicians; and hepatobiliary scintigraphy in abdominal pain.  

The new AUC are intended to assist referring physicians and ordering professionals in fulfilling the requirements of the 2014 Protecting Access to Medicare Act (PAMA). Current regulations call for PAMA to require referring physicians to consult AUC developed by a PLE beginning Jan. 1, 2018, to ensure cost-effective and appropriate utilization of advanced diagnostic imaging services. However, the Centers for Medicare & Medicaid Services has proposed pushing back the start date for when providers will be required to consult AUC to January 2019.

The FDG PET/CT Workgroup consisted of expert representatives from SNMMI, the European Association of Nuclear Medicine (EANM) and the American Society of Clinical Oncology (ASCO). They reviewed the scientific literature and developed consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center conducted a systematic review of existing evidence based on the scope and parameters the PET/CT Workgroup put together, which they used to make their recommendations for clinical use.

The SNMMI Guidance Oversight Committee is also developing AUC for gastrointestinal transit, infection imaging, PET myocardial perfusion imaging, prostate cancer imaging, somatostatin imaging, and thyroid imaging and therapy. 

The full AUC can be viewed here. An abbreviated version of the AUC will be published in the December 2017 issue of The Journal of Nuclear Medicine and is available online ahead of print.

For more information: www.snmmi.org


Related Content

News | Clinical Trials

May 30, 2024 — Researchers from Penn Medicine’s Abramson Cancer Center (ACC) and the Perelman School of Medicine at the ...

Time May 29, 2024
arrow
News | Radiology Business

May 22, 2024 — Medtronic has announced new preliminary data from the VERITAS clinical study using its ILLUMISITE ...

Time May 22, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
Subscribe Now